Search
Displaying 531–540 of 643 for “retinal diseases”
-
Beacon Stories
From stargazing to bird watching, Michael has been an enthusiast of all things science from the age of 12. When Michael was diagnosed with retinitis pigmentosa at 30 years old, he knew he wasn’t going to give up his dream of becoming a record-setting birder. In his own words, Michael shares how he’s overcome his vision loss and continued to pursue his birding passions with “birding-by-ear.”
-
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
Research NewsMore details from the clinical trial will be reported at a later date
-
Research News
Microperimetry, which measures retinal sensitivity in the macular region, shows promise as outcome measure
-
Interim Results Released for USH2A RNA Therapy Clinical Trial
Research NewsSuggestions of efficacy observed in 25 percent of participants receiving the treatment
-
Including the Foundation in your will or trust provides an opportunity to give a larger gift than you may be able to give out of your current assets. By leaving a gift to the Foundation, you can help fight blinding diseases today and for the future.
By leaving a lasting gift, you’re helping the Foundation while retaining the full use of your assets to provide for today’s needs.
-
Simple Ways to Leave Your Legacy
Many people who don’t have the resources to make a significant gift during their lifetime choose to leave a meaningful gift in their will. By leaving a gift to the Foundation, you will provide vital support for the research that will soon find an end to vision loss. You can leave a legacy of sight.
-
Families and Scientists Meet to Discuss Therapy Development for People with RDH12 Mutations
Research NewsProof-of-concept for RDH12 gene therapy demonstrated in mouse model
-
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Research NewsPhase 1/2a human study will evaluate neural progenitors for preserving vision
-
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Research NewsUnlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
-
Acucela Enrolling Patients in Phase 3 Trial for Stargardt Disease Treatment
Research NewsThe Seattle biotech Acucela is now enrolling participants in its Phase 3 clinical trial for emixustat hydrochloride, an emerging oral drug for slowing vision loss in people with Stargardt disease, an inherited form of a macular degeneration.
